China Approval Watch: September Dominated By Generics And Vaccines
Executive Summary
Twenty-three chemical drugs, three biologics and one traditional Chinese medicine are among the latest approvals granted by the China FDA, which is continuing on a hiring spree to increase its number of reviewers.
You may also be interested in...
China Regulatory Watch: New Fast-Track Designations, CTAs
China Regulatory Watch is our new snapshot of product-specific regulatory developments at the China FDA.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.